00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Cerenis HDL: Phase III started

Cerenis began the double-blind, placebo-controlled, international Phase III TANGO trial to evaluate 8 mg/kg IV CER-001 for 48 weeks in about 30 patients. Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France   Product: Cerenis HDL ( CER-001...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Cerenis HDL: Phase II data

An investigator-initiated, open-label, Dutch Phase II trial in 8 patients with atherosclerotic carotid artery disease showed that single doses of 3 mg/kg CER-001 labeled with Zirconium-89 led to a 14% increase in uptake of CER-001...
00:50 , Mar 27, 2015 |  BC Extra  |  Financial News

Cerenis raises EUR 53.4M in Euronext IPO

Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of 4.2 million shares at EUR 12.70 in an IPO on Euronext. The IPO price values Cerenis at EUR 225.9...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

Cerenis HDL regulatory update

Cerenis said the European Commission granted Orphan Drug designation to CER-001 to treat apolipoprotein A-1 (APOA1) and ATP-binding cassette transporter 1 ( ABCA1 ) deficiencies. The company said inherited defects in the APOA1 or ABCA1...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Cerenis HDL: Phase II data

The open-label, Dutch Phase II SAMBA trial in 7 patients with familial primary hypoalphalipoproteinemia showed that IV CER-001 plus optimized LDL-C-lowering therapy significantly increased levels of APOA1 by 23.1 mg/dL and HDL-C by 16.1 mg/dL...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Cerenis HDL: Phase II data

The open-label, international Phase II MODE trial in 23 patients with hoFH showed that 8 mg/kg IV CER-001 plus optimized LDL-C-lowering therapy, including apheresis, met the primary endpoint of reducing carotid artery mean vessel wall...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

CER-001: Phase IIb data

Top-line data from the double-blind, dose-escalation, international Phase IIb CHI-SQUARE trial in 507 patients showed that once-weekly IV CER-001 for 6 weeks missed the primary endpoint of reducing total atheroma volume from baseline to week...